Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 25, Issue 11, 2010, Pages 3701-3706

  Kainz, Alexander ^a,b   Mayer, Bernd ^c   Kramar, Reinhard ^d   Oberbauer, Rainer ^a,b,d  

^a KH Elisabethinen ^*  (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Emergentec Biodevelopment GmbH   (Austria)

^d Austrian Dialysis and Transplant Registry   (Austria)

Author keywords

Cox regression; Erythropoietin; Maintenance haemodialysis; Mortality risk; Spline function

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; ANTIANEMIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; AUSTRIA; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN ANALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT RESPONSE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY;

ADULT; AGED; COHORT STUDIES; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 78649483741     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq287     Document Type: Article

References (37)

1. Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis 1997; 29: 319-333 (Pubitemid 27106553)
2. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997; 51: 622-630 (Pubitemid 27157944)
3. Macdougall IC. Optimizing the use of erythropoietic agents- pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002; 17: 66-70 (Pubitemid 34823076)
4. Macdougall IC, Robson R, Opatrna S et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 1211-1215
5. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590 (Pubitemid 28385655)
6. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084 (Pubitemid 44749316)
7. Pfeffer MA, Burdmann EA, Chen CYet al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
8. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098 (Pubitemid 44749317)
9. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996; 334: 420-425 (Pubitemid 26055841)
10. Goodkin DA, Gimenez LF, Graber SE et al. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: A post hoc analysis. Clin Nephrol 1999; 51: 367-372 (Pubitemid 29261696)
11. Bellizzi V, Minutolo R, Terracciano V et al. Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. Am J Kidney Dis 2002; 40: 549-555 (Pubitemid 34971284)
12. Berns JS, Elzein H, Lynn RI et al. Hemoglobin variability in epoetintreated hemodialysis patients. Kidney Int 2003; 64: 1514-1521 (Pubitemid 37153820)
13. Patel T, Hirter A, Kaufman J et al. Route of epoetin administration influences hemoglobin variability in hemodialysis patients. Am J Nephrol 2009; 29: 532-537
14. Gunnell J, Yeun JY, Depner TA et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-72 (Pubitemid 29031210)
15. Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol 2009; 20: 479-487
16. Yang W, Israni RK, Brunelli SM et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18: 3164-3170 (Pubitemid 350223976)
17. Gilbertson DT, Ebben JP, Foley RN et al. Hemoglobin level variability: Associations with mortality. Clin J Am Soc Nephrol 2008; 3: 133-138
18. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191
19. Kramar R, Oberbauer R. Austrian Dialysis and Transplantation Registry (OEDTR), Annual Report 2008. 2009; Available at http://www. nephro.at/oedr2008/ JB-2008-75.pdf. Last accessed 23 March 2010
20. Kalantar-Zadeh K, Lee GH, Miller JE et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 2009; 53: 823-834
21. Tolman C, Richardson D, Bartlett C et al. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: A randomized clinical study. J Am Soc Nephrol 2005; 16: 1463-1470 (Pubitemid 41716532)
22. Hosmer DW, Lemeshow S. Applied Survival Analysis. Regression Modeling of Time to Event Data. New York, NY: Wiley, 1999
23. Heinze G, Kainz A, Horl WH et al. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: Cohort study. BMJ 2009; 339: B4018
24. Brown ER, Ibrahim JG, DeGruttola V. A flexible B-spline model for multiple longitudinal biomarkers and survival. Biometrics 2005; 61: 64-73 (Pubitemid 40380965)
25. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed 1997; 54: 201-208 (Pubitemid 27496007)
26. Collins AJ, Li S, St Peter W et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12: 2465-2473 (Pubitemid 33021125)
27. Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity-The experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 1998; 13: 1642-1644 (Pubitemid 28306788)
28. Locatelli F, Pisoni RL, Combe C et al. Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132 (Pubitemid 38072623)
29. Lopez-Gomez JM, Portoles JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl 2008; S75-81
30. Miller CB, Jones RJ, Piantadosi S et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322: 1689-1692 (Pubitemid 20231525)
31. 2009. Erythropoiesis-stimulating agents (ESAs): Epoetin alfa (marketed as Procrit and Epogen), Darbepoetin alfa (marketed as Aranesp). Available at http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm054716.htm. Last accessed 23 March 2010
32. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530
33. Kilpatrick RD, Critchlow CW, Fishbane S et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077-1083
34. Kalantar-Zadeh K. Causes and consequences of the reverse epidemiology of body mass index in dialysis patients. J Ren Nutr 2005; 15: 142-147 (Pubitemid 40093699)
35. 2009. NCHS data on obesity. Available at http://www.cdc.gov/nchs/data/ infosheets/infosheet-obesity.htm. Last accessed 23 March 2010
36. Brunelli SM, Joffe MM, Israni RK et al. History-Adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 777-782
37. Brunelli SM, Lynch KE, Ankers ED et al. Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1733-1740